Segall Bryant & Hamill’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-83,980
| Closed | -$5.83M | – | 614 |
|
|
2025
Q1 | $5.83M | Sell |
83,980
-15,203
| -15% | -$1.06M | 0.09% | 290 |
|
|
2024
Q4 | $8.53M | Sell |
99,183
-219,357
| -69% | -$18.9M | 0.12% | 251 |
|
|
2024
Q3 | $37.9M | Buy |
318,540
+93,922
| +42% | +$11.2M | 0.52% | 45 |
|
|
2024
Q2 | $32.1M | Sell |
224,618
-22,735
| -9% | -$3.25M | 0.57% | 41 |
|
|
2024
Q1 | $31.8M | Sell |
247,353
-2,366
| -0.9% | -$304K | 0.6% | 43 |
|
|
2023
Q4 | $25.8M | Sell |
249,719
-364,070
| -59% | -$37.7M | 0.5% | 63 |
|
|
2023
Q3 | $55.8M | Sell |
613,789
-49,259
| -7% | -$4.48M | 0.65% | 32 |
|
|
2023
Q2 | $53.7M | Buy |
663,048
+10,368
| +2% | +$839K | 0.56% | 43 |
|
|
2023
Q1 | $51.9M | Buy |
652,680
+49,568
| +8% | +$3.94M | 0.56% | 44 |
|
|
2022
Q4 | $40.8M | Buy |
603,112
+85,320
| +16% | +$5.77M | 0.46% | 62 |
|
|
2022
Q3 | $25.7M | Buy |
517,792
+512,142
| +9,064% | +$25.4M | 0.31% | 96 |
|
|
2022
Q2 | $315K | Hold |
5,650
| – | – | ﹤0.01% | 657 |
|
|
2022
Q1 | $314K | Buy |
+5,650
| New | +$314K | ﹤0.01% | 671 |
|
|
2021
Q4 | – | Sell |
-5,810
| Closed | -$278K | – | 694 |
|
|
2021
Q3 | $278K | Buy |
5,810
+560
| +11% | +$26.8K | ﹤0.01% | 710 |
|
|
2021
Q2 | $220K | Buy |
+5,250
| New | +$220K | ﹤0.01% | 733 |
|